Abstract
In this study, we compared the in vitro and in vivo neuronal nicotinic acetylcholine receptor (nAChR) properties of 1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-methylindeno[1,2,-b]pyrrole (HDMP, 4) to that of negative allosteric modulator (NAM), PCP. Patch-clamp experiments showed that HDMP exhibited an inhibitory functional activity at α7 nAChRs with an IC(50) of 0.07 μM, and was 357- and 414-fold less potent at α4β2 and α3β4 nAChRs, with IC(50)s of 25.1 and 29.0 μM, respectively. Control patch-clamp experiments showed that PCP inhibited α7, α4β2 and α3β4 nAChRs with IC(50)s of to 1.3, 29.0 and 6.4 μM, respectively. Further, HDMP did not exhibit any appreciable binding affinity to either α7 or α4β2 nAChRs, suggesting its action via a non-competitive mechanism at these neuronal nAChR subtypes. The in vivo study showed that HDMP was a potent antagonist of nicotine-induced analgesia in the tail-flick (AD(50)=0.008 mg/kg), but not in the hot-plate test. All together, our in vitro and in vivo data suggest that HDMP is a novel NAM of neuronal nAChRs with potent inhibitory activity at α7 nAChR subtype at concentrations ≤ 1μM that are not effective for α4β2 and α3β4 nAChRs.
References
May 1, 1992·The Journal of Physiology·P CharnetG Pilar
Mar 1, 1992·British Journal of Pharmacology·J ConnollyS F Heinemann
Jan 1, 1991·The Journal of Physiology·J F MacDonaldP S Pennefather
Jun 8, 1989·European Journal of Pharmacology·D G LambertS R Nahorski
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P Whiting, J Lindstrom
Jan 1, 1995·Psychopharmacology·M I DamajB R Martin
Oct 29, 1993·Journal of Medicinal Chemistry·W GlasscoE L May
Oct 1, 1996·Neurochemical Research·R J Lukas, C M Eisenhour
Dec 15, 1996·Experientia·S J Edelstein, J P Changeux
Apr 15, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·I W WainerK J Kellar
Aug 28, 1999·Neuropharmacology·M W QuickR A Lester
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·C LénaJ P Changeux
Apr 20, 2000·European Journal of Pharmacology·J A DaniV I Pidoplichko
Aug 15, 2000·Behavioural Brain Research·E X AlbuquerqueM Alkondon
Dec 29, 2000·Bioorganic & Medicinal Chemistry Letters·G FerrettiR A Glennon
Apr 16, 2002·Synapse·H A NavarroF I Carroll
May 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jonathan R Genzen, Daniel S McGehee
Jul 10, 2003·Neuroscience·T J PriceC M Flores
Dec 3, 2003·Molecular Pharmacology·J Brek EatonRonald J Lukas
Mar 16, 2004·The Journal of Pharmacology and Experimental Therapeutics·Yingxian Xiao, Kenneth J Kellar
Jul 6, 2004·The Journal of Biological Chemistry·Jie WuRonald J Lukas
Jan 22, 2005·Current Opinion in Pharmacology·Brian J MorrisJudith A Pratt
Jun 1, 2005·Brain Research Bulletin·Ram SackAvi Orr-Urtreger
Mar 1, 2006·Molecular Pharmacology·Galya R AbdrakhmanovaBilly R Martin
Mar 8, 2006·The International Journal of Biochemistry & Cell Biology·Hugo R AriasCecilia Bouzat
Dec 29, 2006·Journal of Molecular Neuroscience : MN·Katrin Susanne LipsWolfgang Kummer
Aug 21, 2007·Biochemical Pharmacology·Daniel Bertrand, Murali Gopalakrishnan
Sep 18, 2007·The Journal of Pharmacology and Experimental Therapeutics·Ryan F YoshimuraKelvin W Gee
Oct 19, 2007·Journal of Neurophysiology·J Russel KeathDaniel S McGehee
Oct 27, 2007·Journal of Neurochemistry·Danyan MaoKenneth J Kellar
Dec 8, 2007·Analytical Chemistry·Ruin MoaddelIrving W Wainer
Feb 12, 2008·Trends in Molecular Medicine·Jean-Pierre Changeux, Antoine Taly
May 1, 2008·Molecular Pharmacology·Jane A DickinsonSusan Wonnacott
Sep 9, 2008·Neuropharmacology·Galya R AbdrakhmanovaBilly R Martin
Jan 20, 2009·American Journal of Respiratory and Critical Care Medicine·Laura PaleariMassimo Fini
May 19, 2009·Acta Pharmacologica Sinica·Yingxian XiaoKenneth J Kellar
Jul 21, 2009·Drug Discovery Today·Laura PaleariPatrizia Russo